<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="237423">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004163</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067405</org_study_id>
    <secondary_id>DFCI-98286</secondary_id>
    <secondary_id>NCI-G99-1628</secondary_id>
    <nct_id>NCT00004163</nct_id>
  </id_info>
  <brief_title>Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer</brief_title>
  <official_title>Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either
      kill them or deliver tumor-killing substances to them without harming normal cells.

      PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who
      have advanced salivary gland cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the response rate to trastuzumab in patients with advanced or
      metastatic salivary gland cancer. II. Determine the time to progression in these patients
      after this regimen. III. Determine the toxicity of trastuzumab in these patients.

      OUTLINE: Patients are stratified according to histology: intercalated duct (adenoid cystic
      carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade
      adenocarcinoma, undifferentiated carcinoma, adenocarcinoma) vs excretory duct (squamous cell
      carcinoma, mucoepidermoid carcinoma). Patients receive trastuzumab IV over 30-90 minutes
      weekly for 4 weeks. Treatment continues in the absence of disease progression or
      unacceptable toxicity. Patients are followed every 3 months.

      PROJECTED ACCRUAL: A total of 50 patients (25 per stratum) will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 1999</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven locally unresectable or metastatic
        malignancy arising from salivary tissue Adenoid cystic carcinoma Polymorphous low grade
        adenocarcinoma Mucoepidermoid carcinoma Undifferentiated carcinoma Acinic cell carcinoma
        Squamous cell carcinoma Malignant mixed tumor Adenocarcinoma Unidimensionally measurable
        disease Overexpression of Her2/neu protein

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Life expectancy:
        Greater than 3 months Hematopoietic: Absolute neutrophil count greater than 1999/mm3
        Platelet count greater than 99,999/mm3 Hemoglobin greater than 8.5 g/dL OR Hematocrit
        greater than 25% Hepatic: Bilirubin less than 2 times upper limit of normal (ULN) SGOT
        less than 2 times ULN (less than 5 times ULN if liver involvement) Alkaline phosphatase
        less than 5 times ULN (no restriction if bone or liver involvement) Renal: Creatinine less
        than 1.5 times ULN OR Creatinine clearance at least 50% lower limit of normal
        Cardiovascular: Must have normal cardiac contractility by MUGA if received prior
        anthracyclines (doxorubicin, daunorubicin, epirubicin) No congestive heart failure
        Pulmonary: No chronic obstructive pulmonary disease Other: No prior other malignancy with
        past 3 years except curatively treated nonmelanoma skin cancer or cervical cancer No
        significant active illness No uncontrolled diabetes No AIDS Not pregnant or nursing
        Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunologic
        therapy No other concurrent immunologic therapy Chemotherapy: No more than 2 prior
        regimens of cytotoxic chemotherapy for salivary gland cancer No prior doxorubicin of more
        than 360 mg/m2 No concurrent chemotherapy Endocrine therapy: At least 4 weeks since prior
        hormonal therapy No concurrent hormonal therapy Radiotherapy: No concurrent radiotherapy
        Surgery: Not specified Other: At least 4 weeks since prior homeopathic, natural, or
        alternative medicine therapy No concurrent homeopathic, natural, or alternative medicine
        therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshall R. Posner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale-New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology/Oncology Associates</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Cod Health Care</name>
      <address>
        <city>Hyannis</city>
        <state>Massachusetts</state>
        <zip>02601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantucket Cottage Hospital</name>
      <address>
        <city>Nantucket</city>
        <state>Massachusetts</state>
        <zip>02554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Barnard Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lourdes Regional Cancer Center</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2001</verification_date>
  <lastchanged_date>February 6, 2009</lastchanged_date>
  <firstreceived_date>December 10, 1999</firstreceived_date>
  <keyword>stage III salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>salivary gland acinic cell tumor</keyword>
  <keyword>low-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>high-grade salivary gland mucoepidermoid carcinoma</keyword>
  <keyword>salivary gland adenocarcinoma</keyword>
  <keyword>salivary gland poorly differentiated carcinoma</keyword>
  <keyword>salivary gland malignant mixed cell type tumor</keyword>
  <keyword>salivary gland adenoid cystic carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Salivary Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
